N01-CM17101/CM/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2002	2
2003	2
2004	5
2005	5
2007	5
2008	2
2009	1
2024	0

1

Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

Davies AM, Lara PN Jr, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. Davies AM, et al. Clin Lung Cancer. 2005 Oct;7 Suppl 2:S59-63. doi: 10.3816/clc.2005.s.010. Clin Lung Cancer. 2005. PMID: 16250929 Review.

2

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

Lara PN Jr, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. Lara PN Jr, et al. Semin Oncol. 2004 Feb;31(1 Suppl 1):40-6. doi: 10.1053/j.seminoncol.2003.12.013. Semin Oncol. 2004. PMID: 14981579 Review.

3

Renal cell carcinoma: current status and emerging therapies.

Nelson EC, Evans CP, Lara PN Jr. Nelson EC, et al. Cancer Treat Rev. 2007 May;33(3):299-313. doi: 10.1016/j.ctrv.2006.12.005. Epub 2007 Feb 27. Cancer Treat Rev. 2007. PMID: 17329029 Review.

4

Current strategies in the management of hormone refractory prostate cancer.

Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Martel CL, et al. Cancer Treat Rev. 2003 Jun;29(3):171-87. doi: 10.1016/s0305-7372(02)00090-7. Cancer Treat Rev. 2003. PMID: 12787712 Review.

5

Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

Lara PN Jr, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. Lara PN Jr, et al. Clin Lung Cancer. 2005 Oct;7 Suppl 2:S67-71. doi: 10.3816/clc.2005.s.012. Clin Lung Cancer. 2005. PMID: 16250931 Review.

6

Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.

Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Gandara DR, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4205s-4209s. doi: 10.1158/1078-0432.CCR-040012. Clin Cancer Res. 2004. PMID: 15217959 Review.

7

Angiogenesis-targeted therapies in prostate cancer.

Lara PN Jr, Twardowski P, Quinn DI. Lara PN Jr, et al. Clin Prostate Cancer. 2004 Dec;3(3):165-73. doi: 10.3816/cgc.2004.n.027. Clin Prostate Cancer. 2004. PMID: 15636683 Review.

8

Inhibition of Akt pathways in the treatment of prostate cancer.

Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr. Nelson EC, et al. Prostate Cancer Prostatic Dis. 2007;10(4):331-9. doi: 10.1038/sj.pcan.4500974. Epub 2007 May 1. Prostate Cancer Prostatic Dis. 2007. PMID: 17471291 Review.

9

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.

Nelson EC, Evans CP, Pan CX, Lara PN Jr. Nelson EC, et al. World J Urol. 2007 Aug;25(4):393-9. doi: 10.1007/s00345-007-0186-3. Epub 2007 Jun 12. World J Urol. 2007. PMID: 17562051 Review.

10

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Chew HK, et al. J Clin Oncol. 2009 May 1;27(13):2163-9. doi: 10.1200/JCO.2008.17.4839. Epub 2009 Mar 23. J Clin Oncol. 2009. PMID: 19307510 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

22 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year